Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose tumor tissue and/or blood samples show no BRAF gene mutation at any point during treatment or follow-up, OR people with a BRAF mutation whose previous Vemurafenib treatment has stopped working.
- People whose disease has not responded to, or has progressed through, earlier treatments — this includes specific combinations of chemotherapy drugs such as Vinblastine, prednisolone, Cytosine Arabinoside, or Cladribine given over a minimum number of weeks or cycles (confirm with trial site for exact treatment history requirements).
- People whose disease came back after initially responding to first-line treatment, or who did not respond to second-line treatment, or whose disease spread to at least one high-risk organ.
- People whose disease continued to progress during or after Vemurafenib treatment.
- People who have developed signs of a neurodegenerative condition seen on a brain and spinal cord scan (MRI).
- People who have signed the required consent forms for trial participation and for treatment with Trametinib, in line with current legal requirements.
- People who are past puberty and sexually active who agree to use effective contraception throughout the treatment period and for at least one year after treatment ends.
- People who are already participating in the HISTIOGEN trial.
Who may not be able to join:
- People who are currently pregnant or breastfeeding.
- People with a known allergy or sensitivity to the study drug (Trametinib) or any of its ingredients.
- People who have certain eye conditions, including iritis, uveitis, or a blockage of the veins in the retina.
- People who are currently taking other medications that may interact with Trametinib.
- People who are still experiencing significant side effects from previous treatments that would make it unsafe to take Trametinib.
- People who have been diagnosed with another cancer before entering the study.
- People with other serious ongoing health conditions, unusual behaviours, or abnormal test results that could increase the risks of being in the trial or affect the trial's results — the trial doctor makes this assessment on a case-by-case basis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Anna Raciborska, Mother and Child Institute
Phone: +48 22 32 77 205
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Event-free survival (EFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.